Platelet vasopressin receptor in patients with chronic renal failure.
The vasopressin binding to intact platelet from patients with chronic renal failure (CRF) was investigated in relation to the abnormalities in platelet aggregation. The immunoreactive arginine vasopressin (AVP) in platelet-free plasma (PFP) but not in platelets was significantly higher in non-dialyzed patients with CRF than in normal subjects. Binding studies using [3H]AVP demonstrated a decreased number of binding sites (Bmax) on platelets from patients with CRF compared to normal controls with no significant difference in affinity (Ka). A significant diminution of the maximal percentage aggregation with AVP was found in patients with CRF. An inverse relation between Bmax and the PFP AVP levels and a highly significant relation between Bmax and the maximal percentage aggregation with AVP in patients with CRF and normal controls were observed. At 4 weeks after the introduction of hemodialysis in patients with CRF, the PFP AVP levels decreased and Bmax increased significantly, and the maximal percentage aggregation tended to increase. The present findings suggest that a reduced number of AVP receptors on platelets might account for decreased platelet aggregation with AVP, and the elevated plasma AVP levels might induce a down-regulation of the AVP receptor number on platelets in patients with CRF.
Inaba
K
K
Umeda
Y
Y
Yamane
Y
Y
Urakami
M
M
Nagata
T
T
Inada
M
M
D000328:Adult; D000368:Aged; D001127:Arginine Vasopressin / Q000097:blood*; D001792:Blood Platelets / Q000032:analysis*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008875:Middle Aged; D011945:Receptors, Angiotensin / Q000032:analysis*; D017483:Receptors, Vasopressin
D011945:Receptors, Angiotensin; D017483:Receptors, Vasopressin; D001127:Arginine Vasopressin